zonisamide has been researched along with Spasms, Infantile in 24 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Spasms, Infantile: An epileptic syndrome characterized by the triad of infantile spasms, hypsarrhythmia, and arrest of psychomotor development at seizure onset. The majority present between 3-12 months of age, with spasms consisting of combinations of brief flexor or extensor movements of the head, trunk, and limbs. The condition is divided into two forms: cryptogenic (idiopathic) and symptomatic (secondary to a known disease process such as intrauterine infections; nervous system abnormalities; BRAIN DISEASES, METABOLIC, INBORN; prematurity; perinatal asphyxia; TUBEROUS SCLEROSIS; etc.). (From Menkes, Textbook of Child Neurology, 5th ed, pp744-8)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs)." | 9.14 | Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. ( Kang, HC; Kim, HD; Lee, JS; Lee, YJ; Seo, JH, 2010) |
| "Zonisamide can reduce spasms in 21% of children with epileptic spasms, without major adverse effects." | 9.12 | Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis. ( Dawman, L; Panda, P; Panda, PK; Sharawat, IK, 2021) |
| "This study investigated the efficacy and safety of zonisamide (ZNS) adjunctive therapy in children with intractable epilepsy to existing antiepileptic drugs (AEDs)." | 5.14 | Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy. ( Kang, HC; Kim, HD; Lee, JS; Lee, YJ; Seo, JH, 2010) |
| "Zonisamide can reduce spasms in 21% of children with epileptic spasms, without major adverse effects." | 5.12 | Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis. ( Dawman, L; Panda, P; Panda, PK; Sharawat, IK, 2021) |
| " However, oral zonisamide appeared to be safe and tolerable in the study." | 2.90 | Safety, tolerability, and effectiveness of oral zonisamide therapy in comparison with intramuscular adrenocorticotropic hormone therapy in infants with West syndrome. ( Angappan, D; Malhi, P; Sahu, JK; Singhi, P, 2019) |
| " The mainstay of treatment is with multiple anti-seizure medications (ASMs); however, the ASMs themselves can be associated with psychobehavioural adverse events, and effects (negative or positive) on cognition and sleep." | 2.82 | Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies. ( Schubert-Bast, S; Strzelczyk, A, 2022) |
| " It included (1) the drugs used for the treatment, (2) their dosage, and (3) the dosage and the schedule of adrenocorticotropic hormone therapy." | 2.73 | Current treatment of West syndrome in Japan. ( Ito, M; Okumura, A; Ozawa, H; Tsuji, T; Watanabe, K, 2007) |
| "The authors evaluated zonisamide for symptomatic infantile spasms in 23 patients." | 2.71 | Zonisamide treatment for symptomatic infantile spasms. ( Lotze, TE; Wilfong, AA, 2004) |
| " The dosage was initially 2-4 mg/kg per day, and then was increased by 2-5 mg/kg every 2-4 days until the seizures disappeared." | 2.69 | Treatment of infantile spasms with zonisamide. ( Hanai, T; Narazaki, O; Yanai, S, 1999) |
| "Vigabatrin has shown promise in treating IS patients, particularly those with tuberous sclerosis." | 2.42 | Pharmacologic treatment of the catastrophic epilepsies. ( Conry, JA, 2004) |
| "In five cases, tonic seizures preceded spasms at a median age of 6 weeks." | 1.51 | New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy. ( Bienvenu, T; Chikvinidze, G; Dulac, O; Epitashvili, N; Gataullina, S; Melikishvili, G; Tabatadze, N, 2019) |
| "Time to relapse was not affected by treatment with ZNS or TPM." | 1.43 | Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit. ( Alayari, A; Anderson, K; Hussain, SA; Lay, J; Rajaraman, RR; Sankar, R, 2016) |
| " The synthetic ACTH dosage was 0." | 1.43 | [Study of the efficacy of low-dose synthetic ACTH therapy without tapering to treat West syndrome]. ( Arai, H; Kodama, K; Omata, T; Tanabe, Y, 2016) |
| "Zonisamide was administered at a starting dose of 2-8 mg/kg/day, increasing by 2-5 mg/kg/day every three to four days until the seizures disappeared or the dose reached 30 mg/kg/day." | 1.35 | Zonisamide in West syndrome: an open label study. ( Ko, TS; Yum, MS, 2009) |
| "We diagnosed interstitial pneumonitis (IP) based on her chest CT and high serum concentrations of KL-6 and surfactant protein D." | 1.34 | [Valproate sodium and zonisamide associated interstitial pneumonitis in an infant]. ( Doi, T; Kato, T; Nikaido, K; Takayama, R, 2007) |
| " We designed three protocols to raise the serum ZNS concentration (SZC): (1) increase the dose in three steps, from 3 to 10 mg/kg every 3 days, (2) increase the dose from 5 to 10 mg/kg over 3-7 days, and (3) start with 10 mg/kg and maintain this dosage for 2 weeks." | 1.33 | Zonisamide for West syndrome: a comparison of clinical responses among different titration rate. ( Funatsuka, M; Hayashi, K; Imai, K; Oguni, H; Osawa, M; Yanagaki, S; Yoshii, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 11 (45.83) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Strzelczyk, A | 1 |
| Schubert-Bast, S | 1 |
| Panda, PK | 1 |
| Sharawat, IK | 1 |
| Panda, P | 1 |
| Dawman, L | 1 |
| Angappan, D | 1 |
| Sahu, JK | 1 |
| Malhi, P | 1 |
| Singhi, P | 1 |
| Melikishvili, G | 1 |
| Epitashvili, N | 1 |
| Tabatadze, N | 1 |
| Chikvinidze, G | 1 |
| Dulac, O | 1 |
| Bienvenu, T | 1 |
| Gataullina, S | 1 |
| Rajaraman, RR | 1 |
| Lay, J | 1 |
| Alayari, A | 1 |
| Anderson, K | 1 |
| Sankar, R | 1 |
| Hussain, SA | 1 |
| Kodama, K | 1 |
| Omata, T | 1 |
| Arai, H | 2 |
| Tanabe, Y | 1 |
| Lee, YJ | 1 |
| Kang, HC | 1 |
| Seo, JH | 1 |
| Lee, JS | 1 |
| Kim, HD | 1 |
| Yum, MS | 1 |
| Ko, TS | 1 |
| Chugani, HT | 1 |
| Asano, E | 1 |
| Sood, S | 1 |
| Kelemen, A | 1 |
| Rásonyl, G | 1 |
| Neuwirth, M | 1 |
| Barcs, G | 1 |
| Szucs, A | 1 |
| Jakus, R | 1 |
| Fabó, D | 1 |
| Juhos, V | 1 |
| Pálfy, B | 1 |
| Halász, P | 1 |
| Lotze, TE | 1 |
| Wilfong, AA | 1 |
| Conry, JA | 1 |
| Yanagaki, S | 1 |
| Oguni, H | 1 |
| Yoshii, K | 1 |
| Hayashi, K | 1 |
| Imai, K | 4 |
| Funatsuka, M | 1 |
| Osawa, M | 1 |
| Nikaido, K | 1 |
| Kato, T | 1 |
| Takayama, R | 1 |
| Doi, T | 1 |
| Tsuji, T | 1 |
| Okumura, A | 1 |
| Ozawa, H | 1 |
| Ito, M | 1 |
| Watanabe, K | 1 |
| Yanagihara, K | 2 |
| Otani, K | 2 |
| Futagi, Y | 1 |
| Suzuki, Y | 3 |
| Nagai, T | 2 |
| Ono, J | 2 |
| Tagawa, T | 2 |
| Abe, J | 2 |
| Shiomi, M | 1 |
| Okada, S | 2 |
| Kawawaki, H | 1 |
| Tomiwa, K | 1 |
| Shiraishi, K | 1 |
| Murata, R | 1 |
| Yanai, S | 1 |
| Hanai, T | 1 |
| Narazaki, O | 1 |
| Kubota, M | 1 |
| Nishi-Nagase, M | 1 |
| Sakakihara, Y | 1 |
| Noma, S | 1 |
| Nakamoto, M | 1 |
| Kawaguchi, H | 1 |
| Yanagisawa, M | 1 |
| Kishi, T | 1 |
| Nejihashi, Y | 1 |
| Kajiyama, M | 1 |
| Ueda, K | 1 |
| Traverse, LD | 1 |
| Toribe, Y | 1 |
| Ueda, H | 1 |
| Shimono, K | 1 |
| Okinaga, T | 1 |
| Matsuoka, T | 1 |
| Morita, Y | 1 |
| Fujikawa, Y | 1 |
| Mano, T | 1 |
4 reviews available for zonisamide and Spasms, Infantile
| Article | Year |
|---|---|
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.
Topics: Autism Spectrum Disorder; Bromides; Cannabidiol; Clobazam; Cognition; Ethosuximide; Everolimus; Felb | 2022 |
Efficacy, tolerability, and safety of zonisamide in children with epileptic spasms: A systematic review and meta-analysis.
Topics: Anticonvulsants; Child; Humans; Prospective Studies; Retrospective Studies; Spasm; Spasms, Infantile | 2021 |
Pharmacologic treatment of the catastrophic epilepsies.
Topics: Anticonvulsants; Child, Preschool; Epilepsies, Myoclonic; Epilepsy; Fructose; Humans; Infant; Isoxaz | 2004 |
Zonisamide in West syndrome.
Topics: Anticonvulsants; Electroencephalography; Humans; Infant; Isoxazoles; Spasms, Infantile; Zonisamide | 2001 |
8 trials available for zonisamide and Spasms, Infantile
| Article | Year |
|---|---|
Safety, tolerability, and effectiveness of oral zonisamide therapy in comparison with intramuscular adrenocorticotropic hormone therapy in infants with West syndrome.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Anticonvulsants; Female; Humans; Infant; Injectio | 2019 |
Efficacy and tolerability of adjunctive therapy with zonisamide in childhood intractable epilepsy.
Topics: Adolescent; Anticonvulsants; Chemotherapy, Adjuvant; Child; Child, Preschool; Dose-Response Relation | 2010 |
Zonisamide treatment for symptomatic infantile spasms.
Topics: Anticonvulsants; Child, Preschool; Electroencephalography; Female; Humans; Infant; Isoxazoles; Male; | 2004 |
Current treatment of West syndrome in Japan.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration | 2007 |
Zonisamide monotherapy in newly diagnosed infantile spasms.
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Drug Administration Schedule; Drug Therapy, Combinatio | 1997 |
[Efficacy of zonisamide in West syndrome].
Topics: Anticonvulsants; Female; Humans; Infant; Isoxazoles; Male; Spasms, Infantile; Zonisamide | 1999 |
Treatment of infantile spasms with zonisamide.
Topics: Anticonvulsants; Electroencephalography; Female; Follow-Up Studies; Humans; Infant; Isoxazoles; Male | 1999 |
Long-term response to zonisamide in patients with West syndrome.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Iso | 2002 |
12 other studies available for zonisamide and Spasms, Infantile
| Article | Year |
|---|---|
New insights in phenomenology and treatment of epilepsy in CDKL5 encephalopathy.
Topics: Anticonvulsants; Child; Child, Preschool; Drug Therapy, Combination; Electroencephalography; Electro | 2019 |
Prevention of infantile spasms relapse: Zonisamide and topiramate provide no benefit.
Topics: Cohort Studies; Electroencephalography; Female; Fructose; Humans; Infant; Isoxazoles; Male; Recurren | 2016 |
[Study of the efficacy of low-dose synthetic ACTH therapy without tapering to treat West syndrome].
Topics: Adrenocorticotropic Hormone; Anticonvulsants; Drug Therapy, Combination; Feasibility Studies; Female | 2016 |
Zonisamide in West syndrome: an open label study.
Topics: Age of Onset; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 2009 |
Infantile spasms: who are the ideal surgical candidates?
Topics: Anticonvulsants; Brain; Electroencephalography; Humans; Infant; Isoxazoles; Magnetic Resonance Imagi | 2010 |
Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Confusion; Disorders of Excessive Somno | 2011 |
Zonisamide for West syndrome: a comparison of clinical responses among different titration rate.
Topics: Anticonvulsants; Drug Administration Schedule; Humans; Infant; Isoxazoles; Spasms, Infantile; Zonisa | 2005 |
[Valproate sodium and zonisamide associated interstitial pneumonitis in an infant].
Topics: Anticonvulsants; Epilepsy; Female; Humans; Infant; Isoxazoles; Lung Diseases, Interstitial; Respirat | 2007 |
[The effect of zonisamide in West syndrome].
Topics: Anticonvulsants; Female; Humans; Infant; Isoxazoles; Male; Spasms, Infantile; Zonisamide | 1995 |
Zonisamide - induced urinary lithiasis in patients with intractable epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Female; Humans; Hydronephrosis; Isoxazoles; Kidney Calculi; Male | 2000 |
Successful zonisamide treatment for infants with hypsarrhythmia.
Topics: Anticonvulsants; Cerebral Cortex; Electroencephalography; Female; Humans; Infant; Isoxazoles; Male; | 2000 |
Successful zonisamide treatment for infants with hypsarrhythmia.
Topics: Humans; Infant; Isoxazoles; Spasms, Infantile; Terminology as Topic; Zonisamide | 2001 |